CD274 and non-small cell lung carcinoma: In a recent network meta-analysis of immunotherapies in first-line advanced NSCLC with PD-L1 ≥50% (4), the base case results comparing EMPOWER-Lung 1 (1), KEYNOTE-024 (5), and KEYNOTE-042 (6) demonstrated cemiplimab was associated with comparable OS and statistically significant improvements in progression-free survival from 6–30 months versus pembrolizumab.